Interest of investigating p53 status in breast cancer by four different methods

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1167-1172

  Thirion, Agnès ^a   Rouanet, Philippe ^a   Thezenas, Simon ^a   Detournay, Damien ^a   Grenier, Jean ^a   Lopez Crapez, Evelyne ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Allelic loss; Breast cancer; Immunohistochemistry; p53; p53 autoantibodies; p53 status; Sequencing

Indexed keywords

COMPLEMENTARY DNA; DNA; PRIMER DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; COLLOID CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; LUNG CARCINOMA; LYMPH NODE; METABOLISM; MIDDLE AGED; NUCLEOTIDE REPEAT; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA PRIMERS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; REPETITIVE SEQUENCES, NUCLEIC ACID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036835703     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1167     Document Type: Article

References (20)

1. Hainaut P and Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137, 2000. (Pubitemid 29439303)
2. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996.
3. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D and Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996. (Pubitemid 26052847)
4. Hahn M, Serth J, Fislage R, Wolfes H, Allhoff E, Jonas V and Pingoud A: Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem 39: 549-550, 1993. (Pubitemid 23099034)
5. Jones MH and Nakamura Y: Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 5: 89-90, 1992.
6. Merlo GR, Cropp CS, Callahan R and Takahashi T: Detection of loss of heterozygosity in tumor DNA samples by PCR. Biotechniques 11: 166-168, 1991.
7. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, et al: The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 19: 4796, 1991.
8. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229, 1984. (Pubitemid 14184314)
9. Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973, 1999. (Pubitemid 29391282)
10. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R and Hainaut P: IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 14: 1-8, 1999. (Pubitemid 29309938)
11. Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, et al: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-35, 1996. (Pubitemid 26026256)
12. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Appl Immunochem 4: 106-116, 1996.
13. Moll UM, Riou G and Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266, 1992.
14. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182, 1996. (Pubitemid 26065829)
15. Delmolino L, Band H and Band V: Expression and stability of p53 protein in normal human mammary epithelial cells. Carcinogenesis 14: 827-832, 1993. (Pubitemid 23169133)
16. Thorlacius S, Thorgilsson B, Bjornsson J, Tryggvadottir L, Borresen AL, Ogmundsdottir HM and Eyfjord JE: TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A: 1856-1861, 1995. (Pubitemid 3000560)
17. Tong D, Kucera E, Schuster E, Schmutzler RK, Swoboda H, Reinthaller A, Leodolter S, et al: Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. Int J Cancer 88: 319-322, 2000.
18. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, et al: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001. (Pubitemid 32685830)
19. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
20. Regele S, Kohlberger P, Vogl FD, Bohm W, Kreienberg R and Runnebaum IB: Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 81: 702-704, 1999. (Pubitemid 29458869)